Please assess the completion status of the following clinical trial:

Trial Title: Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation~* Healthy males and females according to the following criteria:~Based upon a complete medical history, including physical examination, vital signs (BP, PR), 12-lead ECG and clinical laboratory tests (haematology, clinical chemistry and urinalysis).~* Age 18 to 45 years (incl.)~* Body mass index by Quetelet between 18.50 to 24.99 kg/m2 (incl.)~* Female subjects of childbearing potential who agree on using double-barrier contraception during the study. If a female is postmenopausal (no menses for at least 2 years) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) she will be exempt from the requirement. In case of using oral contraceptives, these should be withdrawn at least 2 months before the first drug dosing.~* Male subjects who agree on using effective contraception during the study (barrier contraceptive methods)~Exclusion criteria:~* Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance~* Any laboratory value outside the reference range that is of clinical relevance~* Any evidence of a clinically relevant concomitant disease~* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders~* Positive results of blood tests for infections (HIV, syphilis, hepatitis B or C)~* A positive urine drug screening test at screening and on admission to the trial site in each treatment period.~* A positive alcohol breath test at screening and on admission to the trial site in each treatment period.~* Surgery of the gastrointestinal tract (except appendectomy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Fixed dose combination (Type: EXPERIMENTAL): Linagliptin/Metformin
- Free combination (Type: EXPERIMENTAL): Linagliptin and Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).